tiprankstipranks
Advertisement
Advertisement
Lyell Immunopharma initiated with a Buy at Needham
PremiumThe FlyLyell Immunopharma initiated with a Buy at Needham
21d ago
Lyell Immunopharma: Differentiated Dual‑Target CAR‑T Pipeline and Upcoming Clinical Milestones Support Buy Rating and Acquisition Potential
Premium
Ratings
Lyell Immunopharma: Differentiated Dual‑Target CAR‑T Pipeline and Upcoming Clinical Milestones Support Buy Rating and Acquisition Potential
1M ago
Lyell Immunopharma price target raised to $39 from $32 at Lucid Capital
Premium
The Fly
Lyell Immunopharma price target raised to $39 from $32 at Lucid Capital
2M ago
Lyell Immunopharma: Differentiated CAR-T Durability and Second-Line LBCL Opportunity Underpin Buy Rating and $45 Target
PremiumRatingsLyell Immunopharma: Differentiated CAR-T Durability and Second-Line LBCL Opportunity Underpin Buy Rating and $45 Target
3M ago
Lyell Immunopharma initiates patient dosing in PiNACLE-H2H Phase 3 trial
Premium
The Fly
Lyell Immunopharma initiates patient dosing in PiNACLE-H2H Phase 3 trial
3M ago
Lyell Immunopharma trading resumes
Premium
The Fly
Lyell Immunopharma trading resumes
4M ago
Lyell Immunopharma files to sell 1.9M shares of common stock for holders
PremiumThe FlyLyell Immunopharma files to sell 1.9M shares of common stock for holders
5M ago
Lyell Immunopharma Modernizes Bylaws for Shareholder Engagement
Premium
Company Announcements
Lyell Immunopharma Modernizes Bylaws for Shareholder Engagement
5M ago
Lyell Immunopharma price target raised to $20 from $10 at H.C. Wainwright
Premium
The Fly
Lyell Immunopharma price target raised to $20 from $10 at H.C. Wainwright
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100